About Calcium News

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) issued an approvable letter on May 21 for bazedoxifene, a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis.

The Food and Drug Administration issued a third approvable letter for Wyeth Pharmaceuticals’ experimental drug bazedoxifene, which is being developed under the brand name Viviant to prevent postmenopausal osteoporosis. (WYE)

Wyeth Pharmaceuticals, Collegeville, announced today that it received its third “approvable” letter from the FDA for a drug being developed for the treatment of postmenopausal osteoporosis.